Male Breast Cancer Completed Phase 2 Trials for Cediranib (DB04849)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00244881A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)Treatment